Étiqueté : The Lancet


[Myanmar] Myanmar’s health leaders stand against military rule

Responding to the military coup of Feb 1, 2021, the citizens of Myanmar are on the airwaves, the web, and the streets peacefully protesting their outrage and unreserved rejection of this unlawful and anti-democratic act. Emergency Medicine (EM) doctors have led the resistance through a Civil Disobedience Movement (CDM), minimising work in government hospitals under military rule. The CDM has spread throughout the health workforce, resulting in closure of public hospitals as well as medical and nursing universities. Clinical services have drastically diminished, leading to a health system suddenly in crisis.

The Xinfadi market covers 112 hectares in Beijing’s Fengtai district. © AFP 0

Strengthening public health at the community-level in China

An unprecedented pandemic, COVID-19 is currently hitting the world. After the initial outbreak in the city of Wuhan, Hubei province, COVID-19 is under control in China, with a few small waves caused by imported cases, of which have been stopped in China in 2–4 weeks, with between several cases and hundreds of cases per wave. We have seen clear peak–valley intervals with these small waves. It is crucial to understand why and how China has reached such success because it might help other countries. For COVID-19, we believe that active case finding at the community-level has been the key for China’s achievement. Since the 2003 outbreak of severe acute respiratory syndrome (SARS), health-care reform in China has been focused squarely on community-level capacity building, which compares with countries where community surveillance systems are not ideal.

Two vaccine trials – one by a Chinese team and the other out of Oxford in Britain – have produced an immune response in trial patients. © Xinhua 0

[Chine] In coronavirus vaccine race, Chinese and Oxford trials produce immune responses, offering hope in pandemic

– Phase-two trial by team of Chinese scientists ‘induces significant neutralising antibody responses’, paper in peer-reviewed The Lancet reports

– Study out of Britain’s Jenner Institute finds antibodies are still high up to two months after vaccine administered

Figure 1Spatial distribution of COVID-19 case clusters on the basis of contact tracing data from Guangzhou, China, from Jan 7, 2020, to Feb 18, 2020 @ DR / The Lancet / Elsevier Ltd 0

Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study

As of June 8, 2020, the global reported number of COVID-19 cases had reached more than 7 million with over 400 000 deaths. The household transmissibility of the causative pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains unclear. We aimed to estimate the secondary attack rate of SARS-CoV-2 among household and non-household close contacts in Guangzhou, China, using a statistical transmission model.


SARS-CoV-2 shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series

Background – A cruise ship is a closed-off environment that simulates the basic functioning of a city in terms of living conditions and interpersonal interactions. Thus, the Diamond Princess cruise ship, which was quarantined because of an onboard outbreak of COVID-19 in February, 2020, provides an opportunity to define the shedding pattern of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and patient antibody responses before and after the onset of symptoms.

Des voyageurs, la plupart penchés sur leur téléphone portable, attendent leur train à la gare de Hangzhou dans la province du Zhejiang en Chine, le 30 avril 2020. © LONG WEI / MAXPPP. 0

Essais cliniques du vaccin contre le COVID-19 : la revue The Lancet parle des résultats prometteurs

The Lancet, la revue médicale mondialement connue, a publié le 22 mai le résultat d’un essai du vaccin contre le COVID-19 mis au point par la Chine, premier vaccin du genre à atteindre la phase 1 d’essai clinique. Le test effectué par 21 chercheurs chinois a révélé que le vaccin à adénovirus COVID-19 vectorisé (Ad5-nCov) était sûr, bien toléré par les patients et capable de produire une réponse immunitaire contre le SRAS-CoV-2 chez l’être humain.


[Japon] 日本人は新型コロナウイルスに対して免疫を持っている可能性 低い死亡率の原因?

Une étude du Research Center for Advanced Science and Technology (東京大学 先端科学技術研究センター) de l’Université de Tokyo, présentée en visioconférence le 15 mai 2020 et en cours d’évaluation auprès de la revue médicale The Lancet, estime que le faible taux de décès dus à la covid-19 au Japon pourrait s’expliquer par la présence antérieure d’anticorps IgG chez de nombreux Japonais, anticorps qui auraient été acquis lors de précédentes épidémies de coronavirus dans les années 2000 (SARS, MERS).

Rechercher dans OpenEdition Search

Vous allez être redirigé vers OpenEdition Search